Oculis Holding AG has completed patient randomization in its PREDICT-1 trial testing Licaminlimab, a precision medicine targeting TNFR1-mediated dry eye disease (DED). The trial enrolled 176 patients, two-thirds carrying a genetic variant linked to better response. Licaminlimab showed promising results in Phase 2, improving symptoms and signs of DED, a condition affecting millions with limited effective treatments. Topline results are expected around year-end 2026, potentially marking a shift from trial-and-error to targeted therapy for moderate-to-severe DED patients with the TNFR1 genotype.
Oculis Holding AG's trial progress in dry eye disease comes with this Pluang market snapshot as of Oct 19, 2026 12:01 WIB: Among 150 priced Health-sector US stocks tradable on Pluang, 81 rose and 66 fell today. Notable movers include IDXX at USD 560.36 with a 5.93% increase, COO at USD 57.94 up 5.58%, and LFST at USD 11.74 down 6.23%.
Oculis Holding AG has completed patient randomization in its PREDICT-1 clinical trial testing Licaminlimab, a precision medicine targeting TNFR1-mediated dry eye disease (DED). Two-thirds of the 176 enrolled patients carry a genetic variant linked to...
Ekalia, a joint venture between IBA and Framatome, has signed a collaboration agreement with Telix Pharmaceuticals to accelerate the production of astatine-211 in the United States. Astatine-211 is a promising alpha-emitting radioisotope used in targ...
At ESMO 2026, Roche presented key Phase III trial results showcasing significant advances in cancer treatment. Divarasib demonstrated superior efficacy over first-generation KRAS G12C inhibitors in advanced lung cancer, potentially setting a new stan...
Red Cat Holdings announced a voluntary public purchase offer to acquire all outstanding shares of Steyr Motors AG at €39 per share in cash, representing a significant premium over recent prices. The acquisition aims to strengthen Red Cat's Blue Ops u...
GSK announced that its experimental lung cancer drug, risvutatug rezetecan, achieved a 61% confirmed response rate at the higher 8 mg/kg dose in an early global trial involving patients with relapsed extensive-stage small cell lung cancer. This respo...
